DaVita
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
3% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 79
1% less funds holding
Funds holding: 590 [Q3] → 582 (-8) [Q4]
1.78% less ownership
Funds ownership: 85.31% [Q3] → 83.53% (-1.78%) [Q4]
10% less capital invested
Capital invested by funds: $12.2B [Q3] → $11B (-$1.28B) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 241
73% less call options, than puts
Call options by funds: $149M | Put options by funds: $555M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$169
11%
upside
Avg. target
$169
11%
upside
High target
$169
11%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Barclays Andrew Mok 41% 1-year accuracy 24 / 58 met price target | 11%upside $169 | Equal-Weight Maintained | 18 Feb 2025 |
Financial journalist opinion
Based on 8 articles about DVA published over the past 30 days
Positive
Market Watch
1 day ago
These 15 stocks are the most profitable companies in the S&P 500
Keeping it simple is a good idea when it comes to investing in high-quality, defensive value stocks — especially now.

Negative
The Motley Fool
1 day ago
Warren Buffett Sold These 12 Stocks Over the Past 6 Months: Should You Sell Them Too?
Warren Buffett is known for the stocks he buys. He's had some big winners through the years.

Neutral
Zacks Investment Research
5 days ago
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, DaVita HealthCare (DVA) closed at $151.37, indicating a +0.39% shift from the previous trading day.

Neutral
Zacks Investment Research
6 days ago
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
DVA's stable core business and global expansion are offset by rising labor costs and declining commercial mix, creating a mixed outlook for investors.

Neutral
Zacks Investment Research
6 days ago
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
DaVita HealthCare (DVA) reachead $150.78 at the closing of the latest trading day, reflecting a +0.25% change compared to its last close.

Neutral
Zacks Investment Research
1 week ago
DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know
The latest trading day saw DaVita HealthCare (DVA) settling at $149.83, representing a +0.31% change from its previous close.

Negative
Zacks Investment Research
2 weeks ago
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
DaVita HealthCare (DVA) closed the most recent trading day at $141.12, moving -1.06% from the previous trading session.

Neutral
PRNewsWire
3 weeks ago
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025
DENVER , March 6, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the Barclays Global Healthcare Conference 2025 on Tuesday, March 11, 2025, at 9:00 a.m. EDT. To view the live webcast, visit the Barclays page and create a free registration.

Neutral
GlobeNewsWire
1 month ago
YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities
CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes.

Negative
Reuters
1 month ago
Berkshire Hathaway sells another 750,000 DaVita shares
Warren Buffett's Berkshire Hathaway said it has sold an additional 750,000 shares of DaVita , reducing its stake in the kidney dialysis services provider by about 2% to 35.14 million shares worth $5.4 billion.

Charts implemented using Lightweight Charts™